This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Improving Diagnosis and Treatment of Atopic Dermatitis through Collaborative Primary & Specialist Care

Improving Diagnosis and Treatment of Atopic Dermatitis through Collaborative Primary & Specialist Care

Format

Patient Case Study

Time to Complete

1 hour

Released

March 12, 2019

Expires

March 12, 2020
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Integrity Continuing Education, Inc.

Commercial Supporter

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Program Description

Patients with atopic dermatitis (AD) are sub-optimally managed in current clinical practice and hence report a poor quality of life and high burden from their disease and comorbidities. There is a need to improve the diagnosis, assessment of severity, treatment, and management of AD to enable improved outcomes and quality of life among patients. This program will improve healthcare professionals’ ability to accurately diagnose and recognize AD among patients presenting with eczema by informing participants about updated diagnostic criteria and assessment scores to differentially diagnose AD and its severity. Discussions on updated guidelines, recommendations, and recent clinical evidence will be also included and evaluated to inform treatment decisions that alleviate the symptom burden of AD. Finally, clinicians will learn strategies to improve communication and adherence to treatment, and address the comorbidities of AD.

Intended Audience

This educational initiative has been designed for primary care and family physicians, nurse practitioners, and physician assistants involved in the management of patients with AD.

Educational Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize updated criteria and guidelines to accurately diagnose AD and assess severity in individual patients
  • Review updated guidelines and evaluate available clinical data for therapies utilized in the treatment of AD
  • Describe indications for specialist referral of patients with AD and review best practices for co-management of moderate-to-severe disease with specialist physicians
  • List documentation and prior authorization requirements to ensure access to prescribed medications for patients with AD

Conflict Of Interest Disclosure Policy

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Integrity Continuing Education, Inc. is committed to providing learners with high-quality CME/CE activities and related materials that promote improvement or quality in healthcare and not a specific proprietary business interest or a commercial interest.

Faculty

Jonathan I. Silverberg, MD, PhD, MPH
Associate Professor
Dermatology, Preventive Medicine and Medical Social Services
Director, Multidisciplinary Eczema Center and Patch Testing Clinic
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Dr. Silverberg discloses the following:
Consulting Fees: AbbVie Inc.; Asana BioSciences, LLC; Dermavant Sciences, Inc.; Eli Lilly and Company; Galderma Laboratories, L.P.; GlaxoSmithKline Plc; Glenmark Pharmaceuticals; Incyte Corporation; Kiniksa Pharmaceuticals, Ltd.; Leo Pharma Inc.; Menlo Therapeutics; Pfizer Inc.; Realm Therapeutics, Inc.; Sanofi Genzyme/Regeneron Pharmaceuticals
Fees for Non-CME Services: Sanofi Genzyme/Regeneron Pharmaceuticals
Contracted Research: GlaxoSmithKline Plc

Stephen Brunton, MD
Adjunct Associate Professor
Department of Family Medicine
Touro University
Vallejo, California

Dr. Brunton has no real or apparent conflict of interest to disclose.

Accredited Provider Disclosure

Integrity CE planners and managers have no relevant conflicts of interest to disclose.

Michelle R. Rizzo, ELS (Planner), has no real or apparent conflicts of interest to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation Statement

Integrity Continuing Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals, do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Instructions

There are no fees for participating and receiving CME credit for this activity. During the period of March 12, 2019 through March 12, 2020, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form
A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc., at (855) 835-4004 or information@integrityce.com.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue